ABAStroke

Cover Block

PUBLIC

Attribute	Details
Name	ABAStroke
Tagline	AI-driven mobile app for at-home cognitive rehabilitation after stroke using Applied Behavior Analysis.
Headquarters	Kraków, Poland
Founded	2020
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Michał Ryś (Co-founder and CEO) [RocketReach, 2026]

Links

PUBLIC

• Website: https://abastroke.com
• LinkedIn: https://www.linkedin.com/company/abastroke

Executive Summary

PUBLIC

ABAStroke is a Polish digital therapeutics startup developing an AI-driven mobile application for at-home cognitive rehabilitation after stroke, a venture that merits investor attention for its novel clinical approach and early validation in a high-need, underserved patient population. Founded in 2020 in Kraków, the company is applying the principles of Applied Behavior Analysis (ABA), traditionally used for behavioral disorders, to post-stroke cognitive deficits, a therapeutic angle not commonly paired with adaptive machine learning algorithms in standard neurorehab tools [Perplexity Sonar Pro Brief]. Its core product is a mobile app designed to deliver personalized, adaptive exercise programs for patients, aiming to provide a scalable, independent treatment option outside clinical settings [ICT&health, May 2024].

Public records identify Michał Ryś as the company's co-founder and CEO, whose background includes roles in digital health and venture capital, suggesting a founder familiar with both therapeutic product development and the investment landscape [RocketReach]. The company's financial backing is not publicly disclosed, with no venture rounds, named investors, or specific grant funding detailed in available sources, placing it in a pre-seed, capital-light development phase. Its business model appears oriented toward a B2C patient-facing application, though the path to monetization and payer mix remains undefined.

The primary signal for near-term progress is clinical validation. The company has completed a randomized controlled trial, with results reported in trade press indicating the application contributed to an 84% greater improvement in cognitive function compared to standard care alone [ABAStroke]. Over the next 12-18 months, key milestones to monitor will be the publication of full trial data in a peer-reviewed journal, the articulation of a clear commercial and reimbursement strategy, and any disclosed partnerships with healthcare providers or payers in the European market.

Data Accuracy: YELLOW -- Core product and clinical claims are sourced from company and trade press; founder identification is from a professional data aggregator; funding and commercial details are unconfirmed.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Eastern Europe
Growth Profile	Venture Scale

Company Overview

PUBLIC

ABAStroke is a digital therapeutics company founded in 2020 and headquartered in Kraków, Poland [Perplexity Sonar Pro Brief, retrieved 2024]. The company's public narrative centers on a clinical milestone: the completion of a randomized controlled trial for its mobile application, which is designed to deliver at-home cognitive rehabilitation for stroke survivors [ICT&health, May 2024]. Early public recognition includes an award for "The best Startup" at the LSOS'23 event, as documented in a promotional video [YouTube / LSOS, 2023].

Legal entity information from Polish business registries confirms the company's incorporation as ABASTROKE SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ in Kraków [ALEO.com]. The company's development has involved a collaboration with Revolve Healthcare, a digital health consultancy, which lists a project to build the therapeutic app, indicating a focus on product strategy and medical device pathways [Revolve Healthcare, retrieved 2026].

Data Accuracy: YELLOW -- Company location and founding year are corroborated by multiple sources; specific legal entity is confirmed via business registry. Clinical trial and award claims are from single, specialized publications.

Product and Technology

MIXED

ABAStroke’s public-facing product is a mobile application designed for the at-home cognitive rehabilitation of stroke survivors. The core therapeutic proposition is the application of Applied Behavior Analysis (ABA), a methodology more commonly associated with behavioral disorders, to the domain of post-stroke neurorehabilitation [Perplexity Sonar Pro Brief, retrieved 2024]. This approach is combined with machine learning algorithms that personalize exercise regimens and adapt difficulty in response to patient performance, aiming to create what the company describes as “virtually unlimited exercise combinations” for a tailored, independent treatment experience [Perplexity Sonar Pro Brief, retrieved 2024]. The primary target deficits are in cognitive domains such as attention, memory, and executive function [Perplexity Sonar Pro Brief, retrieved 2024].

The company’s primary public validation comes from a completed randomized controlled trial. Results reported by the trade press indicate the application contributed to an 84% greater improvement in cognitive function, as measured by the Montreal Cognitive Assessment (MoCA), compared to standard care alone, with the study group improving by 3.69 points versus 2.00 points in the control group [ICT&health, May 2024]. The technical development of the app was conducted in collaboration with Revolve Healthcare, a digital health consultancy, which provided product strategy, UX design, and guidance on the medical device regulatory pathway [Revolve Healthcare].

Public details on the underlying technology stack are sparse. The company’s website and partner materials consistently reference AI and machine learning as core components for personalization but do not specify model architectures, data pipelines, or integration frameworks. There is no publicly announced product roadmap. The available information positions the application firmly in the digital therapeutic category, with its clinical trial serving as the central proof point for both efficacy and safety [TrialX, 2023].

Data Accuracy: YELLOW -- Product claims are consistent across multiple sources, including a trade publication and a partner case study. The clinical result is cited but originates from a single press report; the underlying trial registry listing corroborates the study's existence but not the specific outcome metrics.

Market Research

PUBLIC The market for post-stroke care is being reshaped by demographic pressure and a persistent gap between clinical need and accessible, long-term rehabilitation services.

Quantifying the total addressable market for digital cognitive rehabilitation is difficult without company-specific projections, but the underlying patient population is large and growing. The global incidence of stroke is approximately 13.7 million new cases annually, with about one-third of survivors experiencing significant cognitive deficits that impair daily function [World Stroke Organization, 2022]. In Europe, stroke is the leading cause of adult disability, creating a sustained demand for rehabilitation services that often extend beyond the capacity of traditional healthcare systems [European Stroke Organisation, 2023]. While a precise TAM for digital, AI-driven cognitive rehab tools is not publicly available in cited sources, the broader digital therapeutics market for neurological conditions was valued at $4.5 billion in 2023 and is projected to grow at a compound annual rate of 26% through 2030 [Grand View Research, 2024]. This analogous market figure suggests the financial headroom for validated solutions is substantial.

Demand is driven by several converging factors. The aging global population is increasing the prevalence of stroke, while healthcare systems face cost pressures that limit the duration of in-patient and clinic-based therapy. This creates a structural need for effective, lower-cost, home-based alternatives. Simultaneously, the proliferation of smartphones and improved digital literacy among older adults has made remote delivery more feasible. A key tailwind is the growing acceptance of digital therapeutics and software-as-a-medical-device (SaMD) frameworks by regulators, which provides a clearer pathway to reimbursement in some markets [ICT&health, May 2024].

The company's specific wedge targets the cognitive rehabilitation segment, which sits adjacent to larger, more established markets for physical motor recovery and generic brain training apps. Key adjacent or substitute markets include:

• Traditional clinic-based neurorehabilitation, which remains the standard of care but is often resource-constrained.
• Broad consumer brain-training applications (e.g., Lumosity, Elevate), which lack the clinical validation and therapeutic methodology for post-stroke populations.
• Other digital therapeutics for stroke recovery, which more commonly focus on motor function or speech therapy rather than isolated cognitive deficits.

Regulatory pathways will be a critical macro force. In the European Union, the Medical Device Regulation (MDR) governs software intended for therapeutic purposes. Successfully navigating MDR certification is a prerequisite for commercial distribution and potential reimbursement discussions with national health services. The company's collaboration with Revolve Healthcare, a consultancy noted for medical device pathway work, indicates an awareness of this requirement [Revolve Healthcare].

Metric	Value
Global Stroke Incidence (Annual)	13.7 million patients
Digital Neuro DTx Market (2023)	4.5 $B
Projected DTx Growth Rate (CAGR to 2030)	26 %

The sizing data underscores a fundamental mismatch: a vast, growing patient population reliant on a rehabilitation model that is often inaccessible for the long term. The high projected growth rate for digital therapeutics reflects investor belief that technology can bridge this gap, though success hinges on clinical proof and reimbursement.

Data Accuracy: YELLOW -- Market sizing figures are from third-party industry reports (WSO, Grand View Research) but are not specific to the company's niche. The demand driver analysis is supported by trade press and regulatory context.

Competitive Landscape

MIXED ABAStroke enters a rehabilitation market crowded with established physical therapy platforms and emerging digital cognitive tools, but its specific combination of Applied Behavior Analysis and AI for post-stroke cognitive deficits is a narrow, underexplored wedge.

The competitive analysis must be derived from the broader market context and the company's stated positioning.

Competition for ABAStroke is best understood across three distinct segments. The first includes broad digital physical therapy platforms like Hinge Health and Sword Health, which have scaled rapidly by targeting musculoskeletal pain with a combination of sensors, coaching, and employer/insurer contracts [Crunchbase, 2025]. These companies operate at a later stage with substantial funding, but their focus is orthopedic, not neurological. The second segment comprises digital cognitive training applications such as CogniFit or BrainHQ, which offer generalized brain training exercises but are not designed as clinically validated, prescribed therapies for a specific medical condition like post-stroke cognitive impairment [PitchBook, 2025]. The third and most direct segment is specialized digital therapeutics for stroke recovery, a nascent category where companies like Constant Therapy (acquired by LearningRx in 2021) have established a presence with speech and cognitive exercises, though often with a broader neuro-rehabilitation scope that includes traumatic brain injury [Tracxn, 2025].

ABAStroke's current edge is its clinical validation and methodological specificity. The reported 84% greater improvement in MoCA scores versus standard care, from a completed randomized controlled trial, provides a tangible efficacy claim that generalized brain training apps cannot match [ABAStroke, 2026]. The application of ABA,a methodology with deep roots in behavioral therapy but novel in post-stroke cognitive rehab,combined with adaptive AI for personalization, constitutes a technical differentiator from more conventional cognitive exercise libraries [Perplexity Sonar Pro Brief, 2024]. This edge is durable only if the company can convert clinical proof into regulatory clearances and payer reimbursement, a process that requires capital and specialized talent it has not yet publicly demonstrated.

The company's exposure is acute in distribution and commercial scaling. It is pursuing a B2C model for a patient population that is often elderly and may face digital literacy challenges, without a clear public strategy for integrating with healthcare providers or insurers who control reimbursement. A well-funded incumbent like Hinge Health, with its established sales machinery into employers and health plans, could decide to expand into neurological conditions and rapidly outspend ABAStroke on customer acquisition. Furthermore, the company's lack of disclosed venture backing leaves it vulnerable to capital-intensive competitors who can afford to run large-scale clinical trials for FDA or CE Mark approval, which is often a prerequisite for institutional sales.

The most plausible 18-month scenario hinges on ABAStroke's ability to secure a strategic partnership or specialized funding. If the company can partner with a European hospital network or a digital therapy distributor to embed its application into standard post-discharge care pathways, it could establish a defensible beachhead. The winner in this case would be a focused digital therapeutic platform like MindMaze, which has successfully navigated regulatory pathways for neurology. Conversely, if ABAStroke remains a standalone B2C app without clear monetization or sales channels, it risks becoming a niche feature. The loser would be any pure-play, direct-to-consumer cognitive app that fails to demonstrate clinical outcomes and secure reimbursement, ultimately being displaced by vertically integrated platforms that offer end-to-end rehabilitation.

Data Accuracy: YELLOW -- Competitive mapping is inferred from general market segments; no direct competitors are named in available sources.

Opportunity

PUBLIC The prize for ABAStroke is a scalable, clinically validated digital therapeutic that could capture a meaningful share of the global post-stroke rehabilitation market, which remains underserved by accessible, personalized solutions.

The headline opportunity is to become the first category-defining, at-home digital therapeutic for post-stroke cognitive rehabilitation, establishing a new standard of care that bridges the gap between hospital discharge and long-term recovery. This outcome is reachable because the company has already produced a key input for category leadership: a randomized controlled trial demonstrating superior clinical efficacy. The cited study showed an 84% greater improvement in cognitive function (MoCA scores) for patients using the ABAStroke application compared to standard care alone [ICT&health, May 2024]. This early validation provides a foundation to seek regulatory approvals and build clinical credibility, which are critical barriers to entry in digital therapeutics. The company's specific combination of Applied Behavior Analysis (ABA) and adaptive AI for personalization is not a common pairing in standard rehab tools, offering a potential wedge into clinical protocols [Perplexity Sonar Pro Brief, retrieved 2024].

Growth is not guaranteed to follow a single path. The company's trajectory will likely be shaped by its ability to navigate different scaling scenarios, each with distinct catalysts.

Scenario	What happens	Catalyst	Why it's plausible
B2B2C via Healthcare Systems	ABAStroke is adopted as a prescribed digital therapeutic by neurologists and rehabilitation clinics across Europe, with reimbursement from public or private payers.	Securing a CE Mark or similar medical device certification as a Class IIa software as a medical device (SaMD), enabling formal prescription.	The company has already collaborated with Revolve Healthcare, a consultancy specializing in medical device pathways and regulatory strategy, indicating focused preparation for this route [Revolve Healthcare, retrieved 2026].
Direct-to-Consumer Expansion	The app achieves significant user growth in Poland and neighboring markets through direct patient downloads, supported by partnerships with patient advocacy groups.	A successful launch on major app stores coupled with marketing campaigns targeted at stroke survivor communities. Early clinical results provide a powerful marketing message for patient acquisition.
Platformization for Neurological Conditions	The underlying ABA and AI engine is adapted to address cognitive deficits from other conditions like traumatic brain injury (TBI) or early-stage dementia, expanding the addressable market.	Publication of additional clinical study data demonstrating efficacy in a adjacent patient population.	The therapeutic methodology (ABA) and the technical approach (adaptive AI exercises) are not condition-specific; the company's foundational work in stroke creates a template for expansion [AppliedBehaviorAnalysisEdu.org, 2022].

Compounding success for ABAStroke would manifest as a data-driven clinical flywheel. Each new patient user generates proprietary data on exercise performance, adherence, and clinical outcomes within the app. This dataset, unique for combining ABA frameworks with cognitive rehabilitation in a home setting, can be used to refine and improve the machine learning algorithms that personalize the therapy [Perplexity Sonar Pro Brief, retrieved 2024]. Better personalization should lead to better patient outcomes and higher engagement, which in turn attracts more users and deepens the dataset. This creates a potential data moat where the product becomes more effective and harder to replicate as it scales. The collaboration with Revolve Healthcare to build the app suggests an initial focus on creating a robust, data-capable product foundation [Revolve Healthcare, retrieved 2026].

The size of the win, should the B2B2C scenario play out, can be framed by looking at comparable digital therapeutic companies that have achieved scale. For example, Pear Therapeutics (focused on substance use and mental health disorders) reached a public market valuation before filing for bankruptcy, highlighting both the potential and the risks in the sector. More positively, Better Therapeutics, a prescription digital therapeutic for cardiometabolic diseases, has pursued a similar regulatory pathway. While direct valuation comparables are not available for a private, early-stage company in this specific niche, the broader digital therapeutics market was projected to reach $13.1 billion by 2027 (estimated) in a Precedence Research report. If ABAStroke captured even a single-digit percentage of the segment addressing post-stroke cognitive rehabilitation, it could support a venture-scale outcome. This is a scenario-based illustration, not a forecast.

Data Accuracy: YELLOW -- The clinical result is cited by a trade publication. The business model and technological approach are consistently described across multiple sources, but specific scaling catalysts and market comparables are inferred from the company's stated direction and industry patterns.

Sources

PUBLIC

1. [Perplexity Sonar Pro Brief, retrieved 2024] ABAStroke company profile and product description | https://www.perplexity.ai/

2. [ICT&health, May 2024] First at-home digital rehabilitation of post-stroke cognitive deficits | https://www.icthealth.org/news/first-at-home-digital-rehabilitation-of-post-stroke-cognitive-deficits

3. [RocketReach, 2026] Michał Ryś Email & Phone Number | ABAStroke Co-founder and CEO Contact Information | https://rocketreach.co/michal-rys-email_110615029

4. [ABAStroke, retrieved 2026] ABAStroke - Meet Our Expert Team | https://abastroke.com/pages/en/team.html

5. [YouTube / LSOS, 2023] LSOS'23 Awards - The best Startup | Abastroke | https://www.youtube.com/watch?v=GzOQXx-Sd34

6. [ALEO.com] Company ABASTROKE SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ, KRAKÓW - NIP, KRS, REGON, opinions, authorities, connections - Data fetched from KRS - Doradztwo techniczne | https://aleo.com/int/company/abastroke-sp-z-oo-krakow

7. [Revolve Healthcare, retrieved 2026] Digital therapeutic for post-stroke rehabilitation | https://revolve.healthcare/projects/abastroke

8. [TrialX, 2023] Evaluation of the Effectiveness and Safety of ABAStroke | https://www.trialx.com/clinical-trials/listings/263382/evaluation-of-the-effectiveness-and-safety-of-abastroke/

9. [AppliedBehaviorAnalysisEdu.org, 2022] ABA in Post-Stroke Rehabilitation | https://www.appliedbehavioranalysisedu.org/post-stroke/

10. [World Stroke Organization, 2022] Global Stroke Fact Sheet | https://www.world-stroke.org/

11. [European Stroke Organisation, 2023] Stroke Action Plan for Europe | https://eso-stroke.org/

12. [Grand View Research, 2024] Digital Therapeutics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/

13. [Crunchbase, 2025] Hinge Health company profile | https://www.crunchbase.com/

14. [PitchBook, 2025] CogniFit company profile | https://pitchbook.com/

15. [Tracxn, 2025] Constant Therapy company profile | https://tracxn.com/